Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**

Muthusamy Jayaraman(Alnylam Pharmaceuticals (United States)), Michael J. Hope(Acuitas Therapeutics (Canada)), Ismail M. Hafez(University of British Columbia), Xinyao Du(Acuitas Therapeutics (Canada)), Pieter R. Cullis(University of British Columbia), Ying K. Tam(Arbutus Biopharma (Canada)), David Butler(University at Albany, State University of New York), Jayaprakash K. Narayanannair(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Shigeo Matsuda(Alnylam Pharmaceuticals (United States)), Akin Akinc(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Jianxin Chen(Tsinghua University), Steven M. Ansell(Acuitas Therapeutics (Canada)), Mark A. Tracy(Alnylam Pharmaceuticals (United States)), Laxman Eltepu(Alnylam Pharmaceuticals (United States)), Thomas D. Madden(Arbutus Biopharma (Canada)), Barbara L. Mui(Arbutus Biopharma (Canada))
Angewandte Chemie International Edition
July 10, 2012
Cited by 1,219


Related Papers